Neucleus Group Ltd is planning a $20 million U.S. IPO, offering child development assessments in Malaysia. I see NEUC as thinly capitalized, with rapid but low-base revenue growth and heavy dependence on a single product line. The IPO is priced at a steep EV/EBITDA of nearly 55x, despite high risks, limited operating history, and a modest competitive moat.